Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Herzuma + mFOLFOX in HER2+ Biliary Tract Cancer
NCT04722133Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Jun 2020
- Primary completion
- Jun 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in biliary tract cancer (BTC), sponsored by Yonsei University. Started Jun 2020; status: completed.
02
Drugs
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04722133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04722133.